AFP and cancer: Recently, it has been reported that PIVKA‐II serves as a valuable prognostic predictor, transplantation eligibility, resectability, tumor recurrence, therapeutic efficacy, and malignant tumor behaviors [34] and a dual‐positive biomarker model of AFP‐L3 ≥ 15% and DCP ≥ 7.5 ng/mL strongly predicts the risk of early HCC recurrence [35].